



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 10/616,697 07/09/2003 020714-001120US 1586 Michael J. Bennett EXAMINER 20350 7590 03/10/2006 TOWNSEND AND TOWNSEND AND CREW, LLP POPA, ILEANA PAPER NUMBER ART UNIT

TWO EMBARCADERO CENTER **EIGHTH FLOOR** SAN FRANCISCO, CA 94111-3834

1633

DATE MAILED: 03/10/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary		1	Application No.		Applicant(s)		
			10/616,697		BENNETT ET AL.		
		Ē	Examiner		Art Unit		
			Ileana Popa		1633		
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).							
Status						•	
1)[]	Responsive to communication(s) file	ed on .					
·	This action is FINAL . 2b)⊠ This action is non-final.						
/	,—						
,—	closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims							
4)⊠ Claim(s) <u>1-44</u> is/are pending in the application.							
-	4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.							
6) Claim(s) is/are rejected.							
7)	7) Claim(s) is/are objected to.						
8) Claim(s) <u>1-44</u> are subject to restriction and/or election requirement.							
Applicati	on Papers						
9) The specification is objected to by the Examiner.							
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).							
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).							
11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority under 35 U.S.C. § 119							
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
2) Notice 3) Information	et(s) se of References Cited (PTO-892) se of Draftsperson's Patent Drawing Review (I mation Disclosure Statement(s) (PTO-1449 or r No(s)/Mail Date		!	4) Interview Summary Paper No(s)/Mail D 5) Notice of Informal F 6) Other:	ate	O-152)	

Application/Control Number: 10/616,697 Page 2

Art Unit: 1633

DETAILED ACTION

1. Claims 1-44 are pending.

Election/Restrictions

- 2. Claims 2-8, 10, 18-20, 26, 27, 39, 40, and 44 are generic to the following disclosed patentably distinct species:
 - A. Secretory gland (claims 2-6) or organ (claims 7 and 8);

Should secretory gland be elected for prosecution, a further species election is required as follows:

Claims 3-6 are generic to the following disclosed patentably distinct species:

- 1. salivary gland, pancreas, mammary gland, thyroid, thymus, or pituitary gland (claims 3 and 4);
- 2. protein is secreted (claim 5) or is not secreted (claim 6)

Applicant is required under 35 U.S.C. 121 to <u>elect a single disclosed species</u> from both subgroups 1 and 2, even though this requirement is traversed. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Should organ be elected for prosecution, a further species election is required as follows:

1. lung, muscle, brain, blood, breast, bone, bladder, skin, liver, stomach, intestine, kidney, testes, uterus, gastrointestinal tract, or ovaries (claims 7 and 8).

Applicant is required under 35 U.S.C. 121 to <u>elect a single disclosed species of organ</u>, even though this requirement is traversed. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Application/Control Number: 10/616,697

Art Unit: 1633

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

- B. A specific route of administration (claim 10);
- C. Ionizable or ionized transition metal enhancer is a complex, adduct, cluster, or salt (claims 18 and 19);

Should salt be elected for prosecution, a further species election is required as follows:

1. sulfate, acetate, or chloride (claims 20, 26, 27, and 40).

Applicant is required under 35 U.S.C. 121 to <u>elect a single disclosed species of salt</u>, even though this requirement is traversed. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

- D. d-block element, a first row f-block element, aluminum, gallium, zinc,
 nickel, cobalt, or copper (claims 18, 19, 26, 40);
- E. A specific species of protein (claim 39);
- F. A specific species of cationic lipid (claim 44).

The species are independent or distinct because they are drawn to distinct compositions that require different searches in the patent and non-patent literature, and

Art Unit: 1633

a search and examination of anything more than one of the above-designated species would be a serious burden for the examiner.

Applicant is required under 35 U.S.C. 121 to <u>elect a single disclosed species</u> from each group A to F, even though this requirement is traversed. Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species.

MPEP § 809.02(a).

3. Because these inventions are independent or distinct for the reasons given above and the inventions require a different field of search (see MPEP § 808.02), restriction for examination purposes as indicated is proper.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ileana Popa whose telephone number is 571-272-5546. The examiner can normally be reached on 9:00 am-5:30 pm.

Application/Control Number: 10/616,697

Art Unit: 1633

,697 Page 5

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dave Nguyen can be reached on 571-272-0731. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Ileana Popa

ET L. EPPS-FORD, PHA

PRIMARY EXAMINEM